Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,956 questions in 143 reviews · Musculoskeletal
current versionsNo studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
COX‐2 NSAIDs vs placebo Radiographic progression Mean change in mSASSS. Scale from 0 to 72 (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | NR | No studies |
COX‐2 NSAIDs vs placebo Number of serious adverse events · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | RR 0.92 [0.14, 6.21] | 669 participants | Moderate |
Traditional NSAIDs vs placebo Withdrawals due to adverse events Due to adverse events · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | RR 0.75 [0.46, 1.21] | 1165 participants | High |
Traditional NSAIDs vs placebo BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | 190 participants | Moderate |
Traditional NSAIDs vs placebo BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | 356 participants | High |
Traditional NSAIDs vs placebo BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | NR | No studies |
Traditional NSAIDs vs placebo Radiographic progression Mean change in mSASSS. Scale from 0 to 72 (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | NR | No studies |
Traditional NSAIDs vs placebo Number of serious adverse events · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | RR 1.69 [0.36, 7.97] | 671 participants | Moderate |
COX‐2 NSAIDs vs placebo Pain on VAS Scale from 0 to 100 mm (higher is worse) · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | no estimate extracted | 349 participants | High |
COX‐2 NSAIDs vs placebo Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA) Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… (2015) · Cochrane | RR 2.14 [0.36, 12.56] | 669 participants | Low |
Intervention NR Number of patients with at least 30% pain reduction · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | RD 0.1 [0.01, 0.2] | 6 studies · 343 participants | Very low |
Intervention NR Number of patients with a clinically important global improvement · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | RD 0.14 [0.06, 0.23] | 6 studies · 330 participants | Very low |
Intervention NR Fatigue (lower scores mean less fatigue) · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | no estimate extracted | 5 studies · 192 participants | Very low |
Intervention NR Sleep problems (lower scores mean less sleep problems) · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | no estimate extracted | 5 studies · 193 participants | Very low |
Intervention NR Depression (lower scores mean less depression) · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | no estimate extracted | 6 studies · 244 participants | Very low |
Intervention NR Discontinuation due to adverse events · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | RD 0.04 | 5 studies · 284 participants | Very low |
Intervention NR Serious adverse events · Patients with fibromyalgia Selective serotonin reuptake inhibitors for fibromyalgia syndrome (2015) · Cochrane | no estimate extracted | 2 studies · 168 participants | Very low |
Intervention NR ACR 50 American College of Rheumatology improvement criteria · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | RR 3 [1.5, 6] | 1 study · 300 participants | Moderate |
Intervention NR Remission3 · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | no estimate extracted | 1 study · 189 participants | Low |
Intervention NR Functional Status Health Assessment Questionnaire Disability Index . Scale from: 0 to 3 · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | no estimate extracted | 2 studies · 298 participants | Moderate |
Intervention NR Health‐Related Quality of Life at least 20% improvement · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | RR 1.5 [1, 2.1] | 1 study · 263 participants | Moderate |
Intervention NR Radiographic Progression Increase in erosion scores of > 3 units · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | RR 0.31 [0.11, 0.86] | 1 study · 219 participants | Moderate |
Intervention NR Discontinuations due to adverse events · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | RR 2.1 [1.3, 3.3] | 6 studies · 613 participants | High |
Intervention NR Serious Adverse Events · patients with rheumatoid arthritis Methotrexate for treating rheumatoid arthritis (2014) · Cochrane | RR 1.4 [0.36, 5.7] | 2 studies · 330 participants | Moderate |
Intervention NR Pain Global pain 0‐3 (higher scores mean worse) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Intervention NR Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 0.6 [0.39, 0.92] | 1 study · 96 participants | Moderate |
Intervention NR Adverse events Participants (n) withdrew due to adverse effects · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 96 participants | Ungraded |
Intervention NR Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 96 participants | Ungraded |
Intervention NR Radiographic joint changes · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain Global pain VAS 0‐100 (higher scores mean worse) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 47 participants | Moderate |
Intervention NR Function WOMAC‐VAS (Function) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 47 participants | Moderate |
Intervention NR Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 0.9 [0.62, 1.3] | 1 study · 114 participants | Moderate |
Intervention NR Adverse events Participants (n) withdrew due to adverse effects · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 114 participants | Ungraded |
Intervention NR Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 114 participants | Ungraded |
Intervention NR Function Loss of function 0‐3 (higher scores mean worse) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Intervention NR Radiographic joint changes · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain Global pain VAS 0‐100 (higher scores mean worse) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 2 studies · 97 participants | Moderate |
Intervention NR Function WOMAC‐VAS (Function) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 2 studies · 97 participants | Moderate |
Intervention NR Adverse events Participants (n) reported adverse events · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 0.98 [0.14, 6.69] | 2 studies · 97 participants | Moderate |
Intervention NR Adverse events Participants (n) withdrew due to adverse effects · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Radiographic joint changes · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Boswellia serrata vs valdecoxib Pain WOMAC‐VAS (Pain) (higher scores mean worse) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 58 participants | Very low |
Intervention NR Adverse events Participants (n) reported adverse effects · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 5 [0.26, 96.13] | 1 study · 30 participants | Low |
Boswellia serrata vs valdecoxib Function WOMAC‐VAS (Function) · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | no estimate extracted | 1 study · 58 participants | Very low |
Boswellia serrata vs valdecoxib Adverse events Participants (n) reported adverse events · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 2 [0.39, 10.18] | 1 study · 66 participants | Very low |
Boswellia serrata vs valdecoxib Adverse events Participants (n) withdrew due to adverse effects · patients with treating osteoarthritis Oral herbal therapies for treating osteoarthritis (2014) · Cochrane | RR 3 [0.13, 71.07] | 1 study · 66 participants | Very low |